Infliximab in the management of the extra-intestinal manifestations of Crohn's disease [3]

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 11, 2004, Pages 1332-1333

  Lawrance, Ian Craig ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; CASE REPORT; CROHN DISEASE; DRUG EFFICACY; FEMALE; GRANULOMATOUS VASCULITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LETTER; MALE; NEPHROLITHIASIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SACROILIITIS; SCLEROSING CHOLANGITIS;

EID: 8344234997     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03551.x     Document Type: Letter

References (5)

1. Feagan BG, Lichtenstein GR, Mayer LF et al. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Lancet 2002; 359: 1541-9.
2. Kraut A, Blanchard JF, Rawsthorne P et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am. J. Gastroenterol. 2001; 96: 2117-25.
3. Romero-Gomez M, Sanchez-Munoz D. Infliximab induces remission of pyoderma gangrenosum. Eur. J. Gastroenterol. Hepatol. 2002; 14: 907.
4. Christodoulou DK, Katsanos KH, Kitsanou M et al. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig. Liver Dis. 2002; 34: 781-6.
5. Chalvardjian A, Nethercott JR. Cutaneous granulomatous vasculitis associated with Crohn's disease. Cutis 1982; 30: 645-55.